29 / 49
Osimertinib (n=22)
#
SoC (n=19)
Median best percentage change from baseline in
CNS target lesion size: -64% (range -100% to +20%)
Median best percentage change from baseline in
CNS target lesion size: -45% (range -100% to +20%)
Stable disease
Partial response
Progressive disease
Best change from baseline in target
lesion size (%)
-100
-80
-60
-40
-20
0
20
-100
-80
-60
-40
-20
0
20
Best change from baseline in target
lesion size (%)
Not evaluable
Stable disease
Partial response
Complete response
CNS RESPONSE*: CNS EVALUABLE FOR RESPONSE SET
R
R
R
R R R
R
R
R
R
R
R
R
R
R
R
R
Prior brain radiotherapy
R
Prior brain radiotherapy
29
Presented by J Vansteenkiste at ESMO Asia 2017, 17–19 November 2017, Singapore
Proferred Paper Session 1, Abstract LBA5. Ann Oncol 2017;28 (suppl_10): mdx729.007